SLC5A2 and type 2 diabetes mellitus: In addition to addressing comorbidities associated with cardiovascular, renal, and metabolic conditions, the use of SGLT2 inhibitors and GLP-1 receptor agonists has been shown to be effective in patients with type 2 diabetes mellitus (55).